| Dr Marc Yale Burdick, DO | |
|
5350 Tallman Ave Nw, Seattle, WA 98107 | |
| (206) 781-6341 | |
| Not Available |
| Full Name | Dr Marc Yale Burdick |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 19 Years |
| Location | 5350 Tallman Ave Nw, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396864963 | NPI | - | NPPES |
| 100500484 | Medicaid | NV | |
| SL0470 | Other | NV | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | OP60098132 (Washington) | Primary |
| 207P00000X | Emergency Medicine | 4826 (Arizona) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Swedish Medical Center | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ballard Emergency Physicians Ps | 1052209368 | 13 |
News Archive
Today at the 2010 International Microbicides Conference in Pittsburgh, Dezzutti presented the results of tests conducted with five of the most widely used lubricants, chosen from the results of an IRMA web-based survey that collected information on the lubricant preferences of nearly 9,000 men and women from over 100 countries. Dezzutti's findings indicated that some of the products studied had toxic effects on cells and rectal tissue.
Patients who have lower extremity proximal deep vein thrombosis (LE-DVT), or a blood clot in their leg, are increasingly undergoing minimally invasive catheter-based blood clot removal - also referred to as catheter-directed thrombolysis (CDT) - rather than solely being treated with traditional blood-thinning medications (anticoagulation alone).
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.
The perfusion of a burn injury can now rapidly be determined by using a new technique developed by scientists of the University of Twente.
› Verified 4 days ago
| Entity Name | Ballard Emergency Physicians Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619909256 PECOS PAC ID: 1052209368 Enrollment ID: O20040309000049 |
News Archive
Today at the 2010 International Microbicides Conference in Pittsburgh, Dezzutti presented the results of tests conducted with five of the most widely used lubricants, chosen from the results of an IRMA web-based survey that collected information on the lubricant preferences of nearly 9,000 men and women from over 100 countries. Dezzutti's findings indicated that some of the products studied had toxic effects on cells and rectal tissue.
Patients who have lower extremity proximal deep vein thrombosis (LE-DVT), or a blood clot in their leg, are increasingly undergoing minimally invasive catheter-based blood clot removal - also referred to as catheter-directed thrombolysis (CDT) - rather than solely being treated with traditional blood-thinning medications (anticoagulation alone).
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.
The perfusion of a burn injury can now rapidly be determined by using a new technique developed by scientists of the University of Twente.
› Verified 4 days ago
| Entity Name | Cep America Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447484274 PECOS PAC ID: 6608056171 Enrollment ID: O20130213000571 |
News Archive
Today at the 2010 International Microbicides Conference in Pittsburgh, Dezzutti presented the results of tests conducted with five of the most widely used lubricants, chosen from the results of an IRMA web-based survey that collected information on the lubricant preferences of nearly 9,000 men and women from over 100 countries. Dezzutti's findings indicated that some of the products studied had toxic effects on cells and rectal tissue.
Patients who have lower extremity proximal deep vein thrombosis (LE-DVT), or a blood clot in their leg, are increasingly undergoing minimally invasive catheter-based blood clot removal - also referred to as catheter-directed thrombolysis (CDT) - rather than solely being treated with traditional blood-thinning medications (anticoagulation alone).
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.
The perfusion of a burn injury can now rapidly be determined by using a new technique developed by scientists of the University of Twente.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marc Yale Burdick, DO 5350 Tallman Ave Nw, Seattle, WA 98107 Ph: (206) 781-6341 | Dr Marc Yale Burdick, DO 5350 Tallman Ave Nw, Seattle, WA 98107 Ph: (206) 781-6341 |
News Archive
Today at the 2010 International Microbicides Conference in Pittsburgh, Dezzutti presented the results of tests conducted with five of the most widely used lubricants, chosen from the results of an IRMA web-based survey that collected information on the lubricant preferences of nearly 9,000 men and women from over 100 countries. Dezzutti's findings indicated that some of the products studied had toxic effects on cells and rectal tissue.
Patients who have lower extremity proximal deep vein thrombosis (LE-DVT), or a blood clot in their leg, are increasingly undergoing minimally invasive catheter-based blood clot removal - also referred to as catheter-directed thrombolysis (CDT) - rather than solely being treated with traditional blood-thinning medications (anticoagulation alone).
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.
The perfusion of a burn injury can now rapidly be determined by using a new technique developed by scientists of the University of Twente.
› Verified 4 days ago
Sasha Kaiser, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-520-5000 | |
Kristopher Allen Hendershot, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-520-5000 | |
Dr. Lauren Kristen Whiteside, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-744-8464 | |
Brenda Park, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-368-5762 Fax: 814-537-5677 | |
Rhadika Mccormick Souza, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 925 Seneca St, Seattle, WA 98101 Phone: 206-583-6433 Fax: 206-583-6583 | |
Eleanor Ganz, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-598-4955 | |
Dr. Gary H. Somers, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-368-1765 |